Intellipharmaceutics International Inc. – TSX:IPCI.TO
Intellipharmaceutics International stock price today
Intellipharmaceutics International stock price monthly change
Intellipharmaceutics International stock price quarterly change
Intellipharmaceutics International key metrics
Market Cap | 2.64M |
Enterprise value | 4.40M |
P/E | -0.41 |
EV/Sales | 43.01 |
EV/EBITDA | -1.31 |
Price/Sales | 24.21 |
Price/Book | -0.24 |
PEG ratio | N/A |
EPS | -0.10 |
Revenue | 904.94K |
EBITDA | -2.40M |
Income | -3.51M |
Revenue Q/Q | 260.38% |
Revenue Y/Y | 783.05% |
Profit margin | -3877.64% |
Oper. margin | -3696.77% |
Gross margin | 0% |
EBIT margin | -3696.77% |
EBITDA margin | -265.89% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntellipharmaceutics International stock price history
Intellipharmaceutics International stock forecast
Intellipharmaceutics International financial statements
| Nov 2022 | 29.68K | -1.21M | -4110.15% |
|---|---|---|---|
| Feb 2023 | 326.34K | -355.73K | -109.01% |
| May 2023 | 480.20K | -54.12K | -11.27% |
| Aug 2023 | 68.71K | -1.88M | -2749.25% |
| Nov 2022 | 1432032 | 12.00M | 838.58% |
|---|---|---|---|
| Feb 2023 | 1595434 | 12.52M | 785.24% |
| May 2023 | 1735410 | 12.72M | 733.08% |
| Aug 2023 | 1565830 | 14.44M | 922.3% |
| Nov 2022 | -195.92K | 0 | 200K |
|---|---|---|---|
| Feb 2023 | -14.17K | 0 | 0 |
| May 2023 | 89.72K | 0 | 0 |
| Aug 2023 | 240.82K | 0 | 0 |
Intellipharmaceutics International alternative data
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 11 |
| Oct 2023 | 11 |
| Nov 2023 | 11 |
| Dec 2023 | 11 |
| Jan 2024 | 11 |
| Feb 2024 | 11 |
| Mar 2024 | 11 |
| Apr 2024 | 11 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 11 |
Intellipharmaceutics International other data
| Insider | Compensation |
|---|---|
Dr. Amina Odidi Ph.D. (1960) Pres, Chief Operating Officer, Co-Chief Scientific Officer, Acting Chief Financial Officer & Executive Director | $362,510 |
Dr. Isa Odidi M.B.A., Ph.D., MBA (1958) Co-Founder, Chairman, Chief Executive Officer & Co-Chief Scientific Officer | $362,510 |
-
What's the price of Intellipharmaceutics International stock today?
One share of Intellipharmaceutics International stock can currently be purchased for approximately $0.17.
-
When is Intellipharmaceutics International's next earnings date?
Unfortunately, Intellipharmaceutics International's (IPCI.TO) next earnings date is currently unknown.
-
Does Intellipharmaceutics International pay dividends?
No, Intellipharmaceutics International does not pay dividends.
-
How much money does Intellipharmaceutics International make?
Intellipharmaceutics International has a market capitalization of 2.64M.
-
What is Intellipharmaceutics International's stock symbol?
Intellipharmaceutics International Inc. is traded on the TSX under the ticker symbol "IPCI.TO".
-
What is Intellipharmaceutics International's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Intellipharmaceutics International?
Shares of Intellipharmaceutics International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Intellipharmaceutics International's key executives?
Intellipharmaceutics International's management team includes the following people:
- Dr. Amina Odidi Ph.D. Pres, Chief Operating Officer, Co-Chief Scientific Officer, Acting Chief Financial Officer & Executive Director(age: 65, pay: $362,510)
- Dr. Isa Odidi M.B.A., Ph.D., MBA Co-Founder, Chairman, Chief Executive Officer & Co-Chief Scientific Officer(age: 67, pay: $362,510)
-
Is Intellipharmaceutics International founder-led company?
Yes, Intellipharmaceutics International is a company led by its founder Dr. Isa Odidi M.B.A., Ph.D., MBA.
-
How many employees does Intellipharmaceutics International have?
As Jul 2024, Intellipharmaceutics International employs 11 workers.
-
When Intellipharmaceutics International went public?
Intellipharmaceutics International Inc. is publicly traded company for more then 26 years since IPO on 22 Jul 1999.
-
What is Intellipharmaceutics International's official website?
The official website for Intellipharmaceutics International is intellipharmaceutics.com.
-
Where are Intellipharmaceutics International's headquarters?
Intellipharmaceutics International is headquartered at 30 Worcester Road, Toronto, ON.
-
How can i contact Intellipharmaceutics International?
Intellipharmaceutics International's mailing address is 30 Worcester Road, Toronto, ON and company can be reached via phone at +41 67983001.
Intellipharmaceutics International company profile:
Intellipharmaceutics International Inc.
intellipharmaceutics.comTSX
11
Biotechnology
Healthcare
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Toronto, ON M9W 5X2
:
ISIN: CA4581733090
:
